# Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment

> **NCT00422981** · PHASE2 · COMPLETED · sponsor: **Allon Therapeutics** · enrollment: 144 (actual)

## Conditions studied

- Mild Cognitive Impairment, So Stated

## Interventions

- **DRUG:** AL-108
- **DRUG:** AL-108
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00422981
- **Lead sponsor:** Allon Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2012-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00422981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00422981, "Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00422981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*